Affimed to Present at the Jefferies 2019 London Healthcare Conference
November 14 2019 - 6:30AM
Heidelberg, Germany, November 14, 2019 – Affimed
N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company
committed to giving patients back their innate ability to fight
cancer, today announced that Dr. Adi Hoess, CEO, will present at
the Jefferies 2019 London Healthcare Conference on Wednesday,
November 20, 2019 at 3:20 pm GMT / 10:20 am ET in London.
A live audio webcast of the presentation will be
available in the “Webcasts” section on the “Investors” page of the
Affimed website at https://www.affimed.com/investors/webcasts_cp/,
and will be accessible at the same link for 30 days.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical stage
biopharmaceutical company committed to giving patients back their
innate ability to fight cancer. Affimed’s fit-for-purpose ROCK®
platform allows innate cell engagers to be designed for specific
patient populations. The Company is developing single and
combination therapies to treat hematologic and solid tumors. For
more information, please visit www.affimed.com.
Affimed Investor and Media
Contact:
Gregory Gin, Head of Investor RelationsE-Mail:
IR@affimed.com
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Sep 2023 to Sep 2024